DTDagmar Al Tukmachi

Dagmar Al Tukmachi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dagmar Al Tukmachi has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Fecal microRNA signatures as non‐invasive diagnostic and prognostic markers of pediatric inflammatory bowel diseases

    by Tereza Pinkasova, Tereza Deissova, Matej Hrunka, Martina Ambrozova, Dagmar Al Tukmachi, Robin Jugas, Lenka Radova, Julia Bohosova, Tana Machackova, Leos Kren, et al.

    Objectives: The identification of novel noninvasive diagnostic and prognostic biomarkers for pediatric inflammatory bowel disease (PIBD), including pediatric Crohn's disease (pCD) and ulcerative colitis (pUC), is crucial for improving therapeutic outcomes. Given their involvement in PIBD pathogenesis, microRNAs (miRNAs) represent promising candidates. This study investigates their potential diagnostic value and clinical utility. Methods: The study involved 81 treatment‐naive PIBD patients and 30 non‐IBD controls from whom stool samples were collected. Fecal microRNA analysis was performed using small RNA next‐generation sequencing. Differentially expressed miRNAs (DEMs) were identified in the exploratory phase (34 PIBD, 20 non‐IBD children). Logistic regression was used to establish diagnostic and prognostic miRNA expression signatures. The designed miRNA panels were validated using leave‐one‐out cross‐validation and on an independent cohort (47 PIBD, 10 non‐IBD children). Results: A diagnostic signature of four fecal miRNAs (10392‐5p, miR‐1246, miR‐4695‐5p, and miR‐5006‐5p) distinguished pCD from non‐IBD with 79.55% accuracy. Three fecal miRNAs (miR‐1290, miR‐3960, and miR‐5006‐5p) differentiated pUC from non‐IBD with 78.26% accuracy. For treatment‐naïve PIBD patients, panels of five and six miRNAs predicted residual disease activity at 3 months with 100% accuracy for pUC patients and 86.28% accuracy for pCD patients. Additionally, distinct signatures of four and six miRNAs predicted relapse within 12 months with accuracies of 96.87% (pUC) and 88.01% (pCD), respectively. Conclusion: We identified fecal miRNA expression profiles with strong diagnostic and prognostic value in PIBD. These results contribute to improved stratification of disease severity and risk, supporting the advancement of precision and personalized approaches in pediatric IBD management.

  • Open Access

    Tissue MicroRNA Expression Signatures as Diagnostic Biomarkers and Predictors of Residual Disease Activity and Relapse in Treatment-Naïve Pediatric Inflammatory Bowel Disease

    by Tereza Deissova, Dagmar Al Tukmachi, Lenka Radova, Julia Bohosova, Tana Machackova, Leos Kren, Matej Hrunka, Tereza Pinkasova, Martina Ambrozova, Jiri Sana, et al.

    Background: Identifying novel diagnostic and prognostic biomarkers for pediatric inflammatory bowel diseases (PIBD), including Crohn’s disease (pCD) and ulcerative colitis (pUC), is essential for enhancing treatment outcomes. MicroRNAs (miRNAs) have been recognized for their broader relevance in PIBD pathogenesis. This study investigates their diagnostic potential and clinical utility in PIBD. Methods: This prospective, monocentric study, with retrospective validation, involved 119 PIBD patients (58 pCD, 61 pUC) and 39 non-IBD controls. Small RNA next-generation sequencing was performed on fresh-frozen gut biopsies, targeting histopathologically confirmed inflamed areas. Twenty-five dysregulated miRNA candidates were validated via RT-qPCR in formalin-fixed, paraffin-embedded gut biopsies. Logistic regression was used to establish diagnostic and prognostic miRNA expression signatures. Results: A diagnostic signature of 5 miRNAs (miR-223-3p, miR-34a-5p, miR-194-5p, miR-215-5p, miR-338-3p) distinguished pCD from non-IBD with 96.49% accuracy. Two miRNAs (miR-223-3p, miR-194-5p) differentiated pUC from non-IBD with 100% accuracy, and miR-215-5p distinguished pCD from pUC specimens with 83.54% accuracy. For treatment-naïve pCD patients, 7 miRNAs predicted residual disease activity at 3 months with 100% accuracy. Additionally, a distinct signature predicted the risk of relapse within 12 months with an accuracy of 84.21%. Conclusions: In this study, we have established tissue miRNA expression signatures with significant diagnostic and prognostic potential for use in PIBD. These findings aid in stratifying disease severity and risk, paving the way for more precise and personalized management of pediatric IBD.